Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy
- 11 November 2013
- journal article
- research article
- Published by Elsevier in The Breast
- Vol. 23 (1) , 44-49
Abstract
No abstract availableKeywords
Funding Information
- Piedmont Oncology Network
This publication has 23 references indexed in Scilit:
- Trastuzumab Emtansine for HER2-Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- 1st International consensus guidelines for advanced breast cancer (ABC 1)The Breast, 2012
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast CancerNew England Journal of Medicine, 2012
- Survival differences among women with de novo stage IV and relapsed breast cancerAnnals of Oncology, 2010
- Lapatinib plus Capecitabine for HER2-Positive Advanced Breast CancerNew England Journal of Medicine, 2006
- Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study GroupJournal of Clinical Oncology, 2005
- Breast carcinoma survival in Europe and the United StatesCancer, 2003
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- THE ROLE OF CHEMOTHERAPY FOR METASTATIC BREAST CANCERHematology/Oncology Clinics of North America, 1999
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987